Ameriprise
ALXN

Ameriprise’s Alexion Pharmaceuticals ALXN Stock Holding History

Ameriprise’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400,428
Closed -$73.6M – 4022
2021
Q2 		$73.6M Sell
400,428
-15,333
-4% -$2.63M 0.02% 635
2021
Q1 		$63.6M Sell
415,761
-1,934,982
-82% -$299M 0.02% 672
2020
Q4 		$367M Sell
2,350,743
-2,750,143
-54% -$353M 0.13% 167
2020
Q3 		$584M Sell
5,100,886
-935,750
-16% -$101M 0.24% 88
2020
Q2 		$677M Sell
6,036,636
-246,241
-4% -$26.1M 0.29% 68
2020
Q1 		$564M Buy
6,282,877
+60,799
+1% +$5.97M 0.3% 69
2019
Q4 		$673M Buy
6,222,078
+388,344
+7% +$41.5M 0.28% 70
2019
Q3 		$571M Sell
5,833,734
-497,940
-8% -$56.1M 0.26% 77
2019
Q2 		$829M Sell
6,331,674
-572,866
-8% -$73.8M 0.37% 45
2019
Q1 		$933M Sell
6,904,540
-87,752
-1% -$10.9M 0.43% 38
2018
Q4 		$681M Sell
6,992,292
-112,693
-2% -$13.3M 0.34% 54
2018
Q3 		$986M Sell
7,104,985
-350,874
-5% -$44M 0.34% 57
2018
Q2 		$925M Sell
7,455,859
-20,398
-0.3% -$2.38M 0.41% 41
2018
Q1 		$833M Buy
7,476,257
+360,010
+5% +$43M 0.38% 49
2017
Q4 		$850M Buy
7,116,247
+725,946
+11% +$88.4M 0.39% 50
2017
Q3 		$896M Buy
6,390,301
+215,005
+3% +$29.2M 0.43% 37
2017
Q2 		$751M Buy
6,175,296
+25,724
+0.4% +$2.99M 0.38% 48
2017
Q1 		$746M Buy
6,149,572
+454,069
+8% +$58.5M 0.39% 47
2016
Q4 		$697M Buy
5,695,503
+984,796
+21% +$121M 0.38% 49
2016
Q3 		$577M Sell
4,710,707
-1,315,068
-22% -$169M 0.32% 64
2016
Q2 		$704M Buy
6,025,775
+728,182
+14% +$103M 0.41% 48
2016
Q1 		$738M Buy
5,297,593
+92,063
+2% +$13.5M 0.44% 45
2015
Q4 		$993M Sell
5,205,530
-281,475
-5% -$49.2M 0.58% 33
2015
Q3 		$858M Buy
5,487,005
+531,317
+11% +$96.9M 0.53% 35
2015
Q2 		$896M Buy
4,955,688
+1,787,436
+56% +$308M 0.51% 36
2015
Q1 		$549M Buy
3,168,252
+674,172
+27% +$122M 0.32% 68
2014
Q4 		$461M Sell
2,494,080
-470,868
-16% -$87.3M 0.27% 86
2014
Q3 		$492M Buy
2,964,948
+180,277
+6% +$29.6M 0.3% 75
2014
Q2 		$435M Buy
2,784,671
+333,252
+14% +$52.6M 0.26% 96
2014
Q1 		$373M Sell
2,451,419
-191,599
-7% -$30.5M 0.22% 108
2013
Q4 		$352M Buy
2,643,018
+429,491
+19% +$51.5M 0.21% 115
2013
Q3 		$257M Sell
2,213,527
-206,583
-9% -$22.7M 0.17% 147
2013
Q2 		$223M Buy
+2,420,110
New +$233M 0.15% 152

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Ameriprise's ALXN Position: Q3 2021 in Review

Ameriprise sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 400,428 shares — an estimated $73.6M sold.

Ameriprise first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $993M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Ameriprise reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ameriprise sold 400,428 Alexion Pharmaceuticals shares in Q3 2021, an estimated $73.6M.
  • Ameriprise first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Ameriprise's Alexion Pharmaceuticals position peaked at $993M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Ameriprise's 13F filing for Q3 2021, filed 15 Nov 2021.